FDA Lifts Partial Clinical Hold on Gilead Sciences Studies of Magrolimab
On April 12, 2022, Gilead Sciences (GILD) announced that the U.S. FDA lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination with azacitidine. The FDA removed the partial hold after reviewing the comprehensive safety data from each trial.

Enrollment in the U.S. can resume . . .